The 6-week efficacy and safety of atorvastatin versus simvastatin was determined during a
54-week, open-label, multicenter, parallel-arm, treat-to-target study. In all, 1,424 patients …

Abstract The Proceedings of a Canadian Working Group Consensus Conference, first
published in 2011, provided a summary of statin-associated adverse effects and intolerance …

Newman et al 1 review the safety profile of atorvastatin in nearly 10,000 patients involved in
44 clinical trials. Most of these studies included placebo groups or groups treated with …

Background: The safety and tolerability of rosuvastatin were assessed using data from
16,876 patients who received rosuvastatin 5–40 mg in a multinational phase II/III/IIIb/IV …

OBJECTIVE To examine the safety and efficacy of switching from simvastatin to atorvastatin
in patients who had either an inadequate lipid-lowering response with, or an adverse …

2Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Shatin,
Hong Kong 3Division of Cardiology, Department of Internal Medicine, Wan Fang Hospital …

The prevalence of intolerance varies widely. Stopping statin therapy is associated with
worse outcomes in patients with cardiovascular disease. Despite extensive studies, the …

Statins are the first‐line pharmacotherapy for cholesterol reduction. Use of these drugs in
large randomized clinical trials has consistently shown significant reductions in major …

Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins are well
tolerated, but associated with various statin-associated symptoms (SAS), including statin …

Rosuvastatin is a new, synthetic, orally active statin, with marked low-density lipoprotein
(LDL) cholesterol-lowering activity. We conducted 2 dose-ranging studies. In the first study …